NSE
GlaxoSmithKline Pharmaceuticals LimitedGLAXO
GlaxoSmithKline Pharmaceuticals Limited is a leading pharmaceutical company in India, offering a wide range of prescription and over-the-counter medicines. The company focuses on developing innovative treatments for various diseases.
| Key products | Augmentin, Tavizol, Vigilon |
|---|---|
| Geography | India |
| Competitors | Sun Pharma, Cipla, Dr. Reddy's Laboratories |
AI-generated overview — verify before relying on it.
Net institutional flow
No institutional deals
Institutional buyers
0 in / 0 out
High-impact filings
0 · tilt Neutral
Next corporate action
Dividend - Rs 57 Per Share
ex 2026-05-29
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | AUBANK | +₹1,395.8 Cr | 15 | — | — | — | — |
| 2 | ACC | +₹187.8 Cr | 1 | — | — | — | — |
| 3 | GLAXOThis | — | — | — | — | — | — |
| 4 | 3MINDIA | — | — | — | — | — | — |
| 5 | AIAENG | — | — | — | — | +13 | 20 |
| 6 | APLAPOLLO | +₹0 Cr | 2 | — | — | — | — |
| 7 | AWL | +₹0 Cr | 2 | — | — | — | — |
| 8 | ABBOTINDIA | — | — | — | — | +2 | 17 |
| 9 | 360ONE | −₹870.1 Cr | 11 | — | — | +9 | 22 |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
- 2026-06-09FilingGlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper PublicationCompliance
- 2026-06-08FilingGlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding 'Letter for weblink for Annual RepUpdates
- 2026-05-29ActionDividend - Rs 57 Per ShareDividend
- 2025-05-30ActionDividend - Rs 42 Per ShareDividend
- 2024-11-07ActionInterim Dividend - Rs 12 Per ShareDividend
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
- 1
- 2
No bulk/block deals for GLAXO in this window.
News & chatter on GLAXO
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.